The mobile-based test was proven to distinguish between Parkinson’s Disease phenotypes and a greater detection sensitivity than traditional methods.
Boston - September 2021 - Digital health company Linus Health Inc. announces new validation for its digital clock drawing assessment (DCTclock™) in Parkinson’s detection. Two new studies published in the Journal of Parkinson’s Disease and Parkinsonism & Related Disorders demonstrate the assessment’s utility in detecting Parkinson’s and the superiority of DCTclock™ to other standard and widely-used assessments.
Traditional diagnostic methods for Parkinson’s and other cognitive disorders lack the precision doctors need to make the early diagnoses that can impact intervention. DCTclock™ is a Food and Drug Administration (FDA) registered Class II medical device that assesses an individual’s cognitive health by analyzing more than 700 features of a clock drawing process using AI and machine learning. The assessment was already proven effective at detecting Alzheimer’s before the onset of symptoms.
Now, two new studies have validated DCTclock™ for Parkinson’s detection:
-
Parkinsonism & Related Disorders published a study in which the DCTclock™ was found to have greater sensitivity in detecting Parkinson’s in healthy control subjects compared to traditional methods. This study, along with previous and ongoing work, indicates that with the DCTclock™, different forms of neurodegeneration such as Alzheimer’s and Parkinson’s can be identified early and observed over time, which enables treatment to start at the optimal time and its effects be measured over the course of treatment. Furthermore, the DCTclock™ is also very useful to objectively assess the efficacy of promising interventions in clinical trials.
-
In a study published in the Journal of Parkinson’s Disease, researchers found that the digital clock could distinguish between Parkinson’s Disease cognitive phenotypes. They found a higher association of Parkinson’s diagnosis when the clock was drawn slower, and in fewer strokes, compared to a large clock face drawing which had a lower diagnosis rate.
“The DCTclock is being used to advance research into Alzheimer’s with organizations including the Global Alzheimer’s Foundation and the Davos Alzheimer’s Collective. Our goal is to address more areas of cognition and other disorders like Parkinson’s,” said David Bates, PhD and CEO of Linus Health. “With this validation, we’re providing new ways for clinicians and researchers to track and detect cognitive decline and other neurodegenerative diseases without the invasiveness or costs of traditional testing.”
About Linus Health
Linus Health is a digital health company revolutionizing industry understanding of mental and brain health with mobile-based, multimodal testing and monitoring and artificial intelligence analysis. Cognitive tests or those conducted on pen and paper leave critical data out of the picture, the Linus platform combines industry-leading technology, artificial intelligence, and social engagement tools to collect and analyze cognitive and motor function data to provide a patient’s “cognitive footprint.”
Led by an interdisciplinary group of neuroscientists, neurologists, medical practitioners, engineers, and data scientists, Linus Health supports advancement of mental and brain health research, treatment, and care. The company’s multimodal assessments are easily conducted, even outside of clinical settings, to collect a broad range of digital biomarkers from voice and speech patterns, visuospatial memory, dual-tasking ability and fine motor control, as well as movement, balance, and more. By improving mental and brain health testing and access, Linus seeks to make brain health accessible to every patient and give clinicians, caregivers, and researchers the tools to advance detection, care plans, and treatments. Learn more at linushealth.com